$3.79
6.16%
Nasdaq, Sep 05, 10:15 pm CET
ISIN
US09075P1057
Symbol
BTAI

BioXcel Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

BioXcel Therapeutics, Inc. Classifications & Recommendation:

Buy
75%
Hold
17%
Sell
8%

BioXcel Therapeutics, Inc. Price Target

Target Price $11.22
Price $3.79
Potential
Number of Estimates 8
8 Analysts have issued a price target BioXcel Therapeutics, Inc. 2026 . The average BioXcel Therapeutics, Inc. target price is $11.22. This is higher than the current stock price. The highest price target is
$69.30 1,728.50%
register free of charge
, the lowest is .
A rating was issued by 12 analysts: 9 Analysts recommend BioXcel Therapeutics, Inc. to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BioXcel Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the BioXcel Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 2.27 0.81
64.49% 64.25%
EBITDA Margin -2,841.41% -5,623.85%
76.56% 97.92%
Net Margin -2,625.55% -4,415.55%
79.76% 68.18%

8 Analysts have issued a sales forecast BioXcel Therapeutics, Inc. 2025 . The average BioXcel Therapeutics, Inc. sales estimate is

$812k
Unlock
. This is
6.72% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.1m 29.20%
Unlock
, the lowest is
$625k 28.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $2.3m 64.49%
2025
$812k 64.25%
Unlock
2026
$5.7m 597.47%
Unlock
2027
$56.2m 892.79%
Unlock
2028
$93.2m 65.77%
Unlock
2029
$165m 76.61%
Unlock
2030
$88.5m 46.20%
Unlock
2031
$148m 66.87%
Unlock
2032
$199m 35.05%
Unlock

5 Analysts have issued an BioXcel Therapeutics, Inc. EBITDA forecast 2025. The average BioXcel Therapeutics, Inc. EBITDA estimate is

$-45.6m
Unlock
. This is
8.45% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-43.4m 13.01%
Unlock
, the lowest is
$-50.5m 1.36%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-64.5m 61.45%
2025
$-45.6m 29.24%
Unlock
2026
$-49.4m 8.15%
Unlock
2027
$-29.8m 39.67%
Unlock
2028
$-39.0m 30.84%
Unlock
2029
$10.7m 127.49%
Unlock
2030
$23.1m 115.24%
Unlock
2031
$74.8m 224.34%
Unlock
2032
$120m 60.17%
Unlock

EBITDA Margin

2024 -2,841.41% 76.56%
2025
-5,623.85% 97.92%
Unlock
2026
-872.05% 84.49%
Unlock
2027
-52.99% 93.92%
Unlock
2028
-41.83% 21.06%
Unlock
2029
6.51% 115.56%
Unlock
2030
26.05% 300.15%
Unlock
2031
50.62% 94.32%
Unlock
2032
60.04% 18.61%
Unlock

8 BioXcel Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average BioXcel Therapeutics, Inc. net profit estimate is

$-35.8m
Unlock
. This is
29.68% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-25.5m 49.93%
Unlock
, the lowest is
$-53.0m 4.02%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-59.6m 66.71%
2025
$-35.8m 39.88%
Unlock
2026
$-22.7m 36.56%
Unlock
2027
$-5.4m 76.15%
Unlock
2028
$-6.7m 23.25%
Unlock
2029
$5.5m 181.89%
Unlock

Net Margin

2024 -2,625.55% 79.76%
2025
-4,415.55% 68.18%
Unlock
2026
-401.64% 90.90%
Unlock
2027
-9.65% 97.60%
Unlock
2028
-7.18% 25.60%
Unlock
2029
3.32% 146.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -23.51 -5.41
76.10% 76.99%
P/E negative
EV/Sales 180.43

8 Analysts have issued a BioXcel Therapeutics, Inc. forecast for earnings per share. The average BioXcel Therapeutics, Inc. EPS is

$-5.41
Unlock
. This is
16.64% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.85 40.68%
Unlock
, the lowest is
$-8.01 23.42%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-23.51 76.10%
2025
$-5.41 76.99%
Unlock
2026
$-3.43 36.60%
Unlock
2027
$-0.82 76.09%
Unlock
2028
$-1.01 23.17%
Unlock
2029
$0.83 182.18%
Unlock

P/E ratio

Current -0.58 154.36%
2025
-0.70 19.86%
Unlock
2026
-1.10 57.14%
Unlock
2027
-4.63 320.91%
Unlock
2028
-3.75 19.01%
Unlock
2029
4.59 222.40%
Unlock

Based on analysts' sales estimates for 2025, the BioXcel Therapeutics, Inc. stock is valued at an EV/Sales of

180.43
Unlock
and an P/S ratio of
67.98
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 168.30 462.50%
2025
180.43 7.21%
Unlock
2026
25.87 85.66%
Unlock
2027
2.61 89.93%
Unlock
2028
1.57 39.68%
Unlock
2029
0.89 43.38%
Unlock
2030
1.65 85.89%
Unlock
2031
0.99 40.07%
Unlock
2032
0.73 25.95%
Unlock

P/S ratio

Current 63.41 507.38%
2025
67.98 7.21%
Unlock
2026
9.75 85.66%
Unlock
2027
0.98 89.93%
Unlock
2028
0.59 39.67%
Unlock
2029
0.34 43.39%
Unlock
2030
0.62 85.92%
Unlock
2031
0.37 40.07%
Unlock
2032
0.28 25.96%
Unlock

Current BioXcel Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 19 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 15 2025
LUCID CAPITAL MARKETS
Locked
Locked
Locked Jul 15 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 23 2025
Rodman & Renshaw
Locked
Locked
Locked Mar 19 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 30 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 19 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 15 2025
Locked
LUCID CAPITAL MARKETS:
Locked
Locked
Jul 15 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 23 2025
Locked
Rodman & Renshaw:
Locked
Locked
Mar 19 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 30 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today